IL182493A0 - Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists - Google Patents

Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists

Info

Publication number
IL182493A0
IL182493A0 IL182493A IL18249307A IL182493A0 IL 182493 A0 IL182493 A0 IL 182493A0 IL 182493 A IL182493 A IL 182493A IL 18249307 A IL18249307 A IL 18249307A IL 182493 A0 IL182493 A0 IL 182493A0
Authority
IL
Israel
Prior art keywords
preventing
receptor antagonists
adenosine receptor
pulmonary inflammation
airway remodeling
Prior art date
Application number
IL182493A
Other languages
English (en)
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of IL182493A0 publication Critical patent/IL182493A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL182493A 2004-10-15 2007-04-12 Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists IL182493A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61943904P 2004-10-15 2004-10-15
PCT/US2005/036950 WO2006044610A1 (en) 2004-10-15 2005-10-14 Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
IL182493A0 true IL182493A0 (en) 2007-09-20

Family

ID=35677798

Family Applications (1)

Application Number Title Priority Date Filing Date
IL182493A IL182493A0 (en) 2004-10-15 2007-04-12 Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists

Country Status (13)

Country Link
US (2) US20060159627A1 (https=)
EP (2) EP1799221A1 (https=)
JP (2) JP2008516969A (https=)
KR (1) KR20070063548A (https=)
CN (1) CN101039677A (https=)
AU (1) AU2005295654B2 (https=)
CA (1) CA2583986A1 (https=)
IL (1) IL182493A0 (https=)
MX (1) MX2007004373A (https=)
NO (1) NO20072466L (https=)
NZ (2) NZ554485A (https=)
RU (1) RU2391103C2 (https=)
WO (1) WO2006044610A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
CA2671940A1 (en) * 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
NZ537975A (en) * 2002-07-29 2007-08-31 Cv Therapeutics Inc Method of producing coronary vasodilation without peripheral vasodilation comprising administering at least 10 mcg of at least one A2A receptor agonist
KR101222364B1 (ko) * 2003-08-25 2013-01-15 트로비스 파마슈티칼스 엘엘씨 치환된 8-헤테로아릴 크산틴
KR20070083714A (ko) * 2004-10-20 2007-08-24 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ2ａ 아데노신 수용체 작용제의 용도
US7618962B2 (en) * 2005-02-25 2009-11-17 Pgx Health, Llc Pyrazolyl substituted xanthines
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
WO2006091936A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
NZ564326A (en) * 2005-06-16 2010-01-29 Cv Therapeutics Inc Prodrugs of A2B adenosine receptor antagonists
WO2008051260A1 (en) * 2006-01-13 2008-05-02 Battelle Memorial Institute Methods for assessing copd-retlated diseases
US7732595B2 (en) 2006-02-03 2010-06-08 Gilead Palo Alto, Inc. Process for preparing an A2A-adenosine receptor agonist and its polymorphs
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
RU2459626C2 (ru) * 2006-09-01 2012-08-27 Гайлид Сайэнсиз, Инк. Способы и композиции, повышающие переносимость пациентом методов визуализации миокарда
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
US20080170990A1 (en) * 2006-09-29 2008-07-17 Cv Therapeutics, Inc. Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease
JP2010515081A (ja) * 2007-01-03 2010-05-06 ギリアード・パロ・アルト・インコーポレイテッド 心筋灌流画像化
JP5460690B2 (ja) * 2008-03-26 2014-04-02 アドヴィナス・セラピューティックス・リミテッド アデノシンレセプターアンタゴニストとしてのヘテロ環化合物
AU2009296235A1 (en) * 2008-09-29 2010-04-01 Gilead Sciences, Inc. Combinations of a rate control agent and an A-2-alpha receptor antagonist for use in multidetector computed tomography methods
AU2010222289B2 (en) 2009-03-13 2013-07-11 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
US20120003329A1 (en) * 2010-06-30 2012-01-05 Gilead Sciences, Inc. Use of A2B Adenosine Receptor Antagonists for Treating Pulmonary Hypertension
AR085942A1 (es) 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
CN107249630A (zh) * 2014-11-24 2017-10-13 国家健康与医学研究院 通过il‑20r的拮抗作用治疗慢性阻塞性肺疾病的急性加重
ES2580702B1 (es) 2015-02-25 2017-06-08 Palobiofarma, S.L. Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
MX2020009286A (es) 2018-03-05 2020-12-11 Teon Therapeutics Inc Antagonistas del receptor de adenosina y usos de los mismos.
CN116322698A (zh) * 2020-09-04 2023-06-23 泰昂治疗公司 腺苷a2b受体拮抗剂的共晶

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5854081A (en) 1996-06-20 1998-12-29 The University Of Patent Foundation Stable expression of human A2B adenosine receptors, and assays employing the same
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
US6815446B1 (en) 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
DE60001969T2 (de) * 1999-08-31 2004-02-05 Vanderbilt University, Nashville Selektive antagonisten von a2b adenosinrezeptoren
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
EP1255550A2 (en) 2000-02-17 2002-11-13 Cv Therapeutics, Inc. Method for identifying and using a 2b adenosine receptor antagonists to mediate mammalian cell proliferation
US6387913B1 (en) * 2000-12-07 2002-05-14 S. Jamal Mustafa Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists
US7304070B2 (en) 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080318983A1 (en) 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
ATE520694T1 (de) * 2001-11-09 2011-09-15 Gilead Palo Alto Inc A2b-adenosinrezeptorantagonisten
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6933298B2 (en) * 2001-12-08 2005-08-23 Aventis Pharma Deutschland Gmbh Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases
CN1620294A (zh) * 2001-12-20 2005-05-25 Osi药物公司 嘧啶a2b选择性拮抗剂化合物,它们的合成及用途
AU2003223497A1 (en) * 2002-04-05 2003-10-27 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
ES2229928B1 (es) 2003-10-02 2006-07-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirimidin-2-amina.
US7449473B2 (en) 2003-10-31 2008-11-11 Cv Therapeutics, Inc. Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists
US20060058322A1 (en) 2004-09-01 2006-03-16 Dewan Zeng Method of wound healing using A2B adenosine receptor antagonists
NZ564326A (en) 2005-06-16 2010-01-29 Cv Therapeutics Inc Prodrugs of A2B adenosine receptor antagonists
WO2007109547A2 (en) 2006-03-17 2007-09-27 Cv Therapeutics, Inc. Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists

Also Published As

Publication number Publication date
WO2006044610A1 (en) 2006-04-27
KR20070063548A (ko) 2007-06-19
MX2007004373A (es) 2007-08-08
US20060159627A1 (en) 2006-07-20
NO20072466L (no) 2007-05-14
RU2391103C2 (ru) 2010-06-10
JP2008516969A (ja) 2008-05-22
RU2007117907A (ru) 2008-11-20
AU2005295654B2 (en) 2011-04-14
US20100105706A1 (en) 2010-04-29
NZ554485A (en) 2010-12-24
CA2583986A1 (en) 2006-04-27
NZ589657A (en) 2012-06-29
EP1799221A1 (en) 2007-06-27
CN101039677A (zh) 2007-09-19
JP2012056965A (ja) 2012-03-22
EP2311462A1 (en) 2011-04-20
AU2005295654A1 (en) 2006-04-27
US8466129B2 (en) 2013-06-18

Similar Documents

Publication Publication Date Title
IL182493A0 (en) Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists
ZA200807894B (en) Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists
ZA200701777B (en) Method of wound healing using A2B adenosine receptor antagonists
IL181325A0 (en) Air-launchable aircraft and method of use
GB0509126D0 (en) Internal riser inspection system, apparatus and methods of using same
GB2413184B (en) Internal riser inspection device and methods of using same
IL182115A0 (en) Steroid analogs and characterization and treatment methods
ZA200701635B (en) Quinazolinone derivatives and their use as B-Raf inhibitors
AU2003273300A8 (en) Modified glp-1 receptor agonists and their pharmacological methods of use
ZA201000055B (en) Non-basic melanin concentration hormone receptor-1 antagonists and methods
ZA200701366B (en) Quinazolinone derivatives and their use as B-Raf inhibitors
GB0508218D0 (en) Online thermal and watercut management
GB2447581B (en) Articulated drillstring entry apparatus and method
EP1827391A4 (en) DOSAGE FORMS AND METHODS OF USE THEREOF
GB0514950D0 (en) Downhole measurement system and method
IL181898A0 (en) Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
GB0611154D0 (en) Novel receptor antagonists and their methods of use
EP1811713A4 (en) METHOD FOR DETERMINING THE CLOCK TRACKING PATH AND METHOD FOR TAKING TRACKING IN THE NETWORK
GB0707743D0 (en) Rock bolt and method of use
PL1786744T3 (pl) Sposób opóźniania wiązania gipsu i preparatów gipsowych
PL1751175T3 (pl) Antagoniści receptora IL-1, kompozycje i sposoby leczenia
IL178785A0 (en) Methods of using and compositions comprising thalidomide for the treatment and management of pulmonary hypertension
GB2454112B (en) Apparatus and method for use in suspending loads in wellbore operations
EP1838730A4 (en) PAN-HER ANTAGONISTS AND METHODS OF USE
HK1109728A (en) Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists